F6777
Flecainide acetate salt
≥98% (HPLC), powder, sodium channel blocker
동의어(들):
N-(2-Piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide acetate salt
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C17H20F6N2O3 · C2H4O2
CAS 번호:
Molecular Weight:
474.39
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
258-997-5
MDL number:
Quality level:
제품 이름
Flecainide acetate salt,
Quality Level
originator
Medicis
storage temp.
2-8°C
SMILES string
CC(O)=O.FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2
InChI
1S/C17H20F6N2O3.C2H4O2/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11;1-2(3)4/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26);1H3,(H,3,4)
InChI key
RKXNZRPQSOPPRN-UHFFFAOYSA-N
Gene Information
human ... SCN5A(6331)
관련 카테고리
Biochem/physiol Actions
Class IC antiarrhythmic agent; sodium channel blocker
Features and Benefits
This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Medicis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
저장 등급
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Drug therapy. Flecainide.
D M Roden et al.
The New England journal of medicine, 315(1), 36-41 (1986-07-03)
P Somani
Clinical pharmacology and therapeutics, 27(4), 464-470 (1980-04-01)
A new class I antiarrhythmic, flecainide, was investigated in 10 patients to assess short-term efficacy and safety. All patients were hospitalized for 3 days; no antiarrhythmics were given on days 1 and 3. On day 2 flecainide 1 mg/kg was
The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.
Naomasa Makita et al.
The Journal of clinical investigation, 118(6), 2219-2229 (2008-05-03)
Phenotypic overlap of type 3 long QT syndrome (LQT3) with Brugada syndrome (BrS) is observed in some carriers of mutations in the Na channel SCN5A. While this overlap is important for patient management, the clinical features, prevalence, and mechanisms underlying
Kosuke Doki et al.
Pharmacogenetics and genomics, 22(11), 777-783 (2012-09-04)
To investigate the association between age-related decline in flecainide clearance and CYP2D6 genotype, we conducted a population pharmacokinetic analysis of flecainide using routine therapeutic drug monitoring data. Population pharmacokinetic analysis was performed on retrospective data from 163 genotyped patients treated
Nian Liu et al.
Trends in cardiovascular medicine, 22(2), 35-39 (2012-08-08)
Recent studies have shown that flecainide may be an effective therapy to prevent life-threatening arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. Several hypotheses have been advanced to explain the antiarrhythmic mechanism of flecainide, including Na(+) channel blockade and a
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.